PyrG (CTP synthase) catalyses the conversion of UTP to CTP, an essential step in the pyrimidine metabolic pathway in a variety of bacteria, including those causing community-acquired respiratory tract infections (RTIs). In this study, a luminescence-based ATPase assay of PyrG was developed and used to evaluate the inhibitory activity of 2-(3-[3-oxo-1,2-benzisothiazol-2(3H)-yl]phenylsulfonylamino) benzoic acid (compound G1). Compound G1 inhibited PyrG derived from Streptococcus pneumoniae with a 50 % inhibitory concentration value of 0.091 mM, and the inhibitory activity of compound G1 was 13 times higher than that of acivicin (1.2 mM), an established PyrG inhibitor. The results of saturation transfer difference analysis using nuclear magnetic resonance spectroscopy suggested that these compounds compete with ATP and/or UTP for binding to Strep. pneumoniae PyrG. Finally, compound G1 was shown to have antimicrobial activity against several different bacteria causing RTIs, such as Staphylococcus aureus and Haemophilus influenzae, suggesting that it is a prototype chemical compound that could be harnessed as an antimicrobial drug with a novel structure to target bacterial PyrG.
INTRODUCTION
Although numerous antibiotics for community-acquired bacterial respiratory tract infections (RTIs) have been discovered, most target the same or functionally similar molecules essential for bacterial growth. As emerging antibiotic-resistant bacteria, such as multidrug-resistant Strep. pneumoniae and b-lactamase-negative and ampicillin-resistant Haemophilus influenzae, are posing threats, especially to immunocompromised patients, there is an unmet medical need to provide antibiotics with novel modes of action to reduce infections associated with such bacteria.
Recent progress in genome projects (Fleischmann et al., 1995; Hoskins et al., 2001; Kuroda et al., 2001) has decoded the genomic structure of a variety of organisms, such as Strep. pneumoniae, Staphylococcus aureus and H. influenzae, creating opportunities to design molecular targeting strategies to discover agents that specifically attack these pathogens. In fact, a number of studies in pharmaceutical companies and in academia have developed screening platforms based on enzymic assays and structure-based drug design. As a result, inhibitors that target enzymes such as N-acetylglucosamine-1-phosphate uridyltransferase (GlmU), NAD + -dependent DNA ligases (LigA), enoyl-(acyl-carrier-protein) reductase (FabI) and met tRNA synthase, as well as those that inhibit cell-wall synthesis, have been discovered and validated for their antimicrobial activity (Silver, 2003; Payne et al., 2007; Meier et al., 2008; Pereira et al., 2009) .
In this study, we evaluated the inhibitory activity of 2-(3-[3-oxo-1,2-benzisothiazol-2(3H)-yl]phenylsulfonylamino) benzoic acid (compound G1; Fig. 1 ) as a potential antimicrobial agent by targeting the bacterial CTP synthase PyrG, which serves as a CTP synthase in the de novo pyrimidine biosynthesis pathway (Long & Pardee, 1967; Endrizzi et al., 2004) and is required for growth of certain bacteria such as H. influenzae (Akerley et al., 2002) and Escherichia coli (Gerdes et al., 2003) . Compound G1 was discovered in the course of a 384-well high-throughput screening of a large in-house chemical library by selection of chemicals directly inhibiting PyrG of Strep. pneumoniae. Compounds such as cyclopentenyl cytosine (Lim et al., 1984; Gharehbaghi et al., 1998; Verschuur et al., 2000) , 3-deazauridine (Brockman et al., 1975) and acivicin (Lui et al., 1982) are pyrimidine derivatives or a glutamine analogue, and have been reported to act as PyrG inhibitors. Compound G1 has not been reported as a PyrG inhibitor to date. To test the inhibitory activity of compound G1 against PyrG, we measured the amount of remaining substrate, ATP, using a luminescence-based ATP quantitative reagent. In addition, specificity analysis between compound G1 and Strep. pneumoniae PyrG was carried out by nuclear magnetic resonance (NMR), and susceptibility tests of compound G1 against various bacteria were performed.
METHODS
Test compound. Compound G1 (Enamine) was dissolved in DMSO or DMSO/methanol (70 : 30, v/v) and used in the assays described below.
Bacterial strains and growth conditions. The bacterial strains used in this study are described in Table 1 . Highly competent E. coli DH5a (Toyobo) was used for cloning of PyrG, whilst E. coli RosettaGami B BL21(DE3) (Novagen) was used as the host for recombinant protein expression. These strains were grown at 35 uC in LuriaBertani (LB) broth or LB agar (BD Biosciences) containing 100 mg carbenicillin (Sigma-Aldrich) ml
21
. DNA preparation. Strep. pneumoniae TIGR4 and H. influenzae Rd KW20 (both from ATCC) genomic DNA was extracted using a DNeasy Tissue kit (Qiagen). Plasmid DNA was extracted with a QIAprep Spin Miniprep kit (Qiagen). PCR products and plasmids were digested with restriction enzymes and purified using a QIAquick PCR Purification kit (Qiagen). PCR products were digested with restriction enzymes and purified with a MinElute Reaction Cleanup kit (Qiagen).
Cloning of the pyrG gene. The ORF of the pyrG gene was amplified from Strep. pneumoniae TIGR4 genomic DNA using primers SpPyrG-N-XhoI (59-CCGCTCGAGATGTCTACGAAATATATTTTTGTAA-CTGGTGGTG-39) and SpPyrG-C-XhoI (59-GGCCTCGAGCTAAT-TGCTGTTCTCAACTGCTGC-39). The ORF of pyrG was amplified from H. influenzae Rd KW20 genomic DNA using primers HiPyrG-N-XhoI (59-CCGCTCGAGATGGCTACAAATTATATTTTCGTCA-CTGG-39) and HiPyrG-C-XhoI (59-GGCCTCGAGTTACTTCACAG-ATTTTTTGTGATTTTCATAGGC-39). The PCR products were digested with XhoI and introduced into the pET15b expression vector (Novagen) to form pET15b-SpPyrG and pET15b-HiPyrG, respectively. The sequence of the cloned DNA fragments was verified as the pyrG gene ORF of Strep. pneumoniae (GenBank accession no. AE005672) or of H. influenzae (GenBank accession no. L42023) by DNA sequencing. E. coli Rosetta-Gami B BL21(DE3) was transformed then with pET15b-SpPyrG or pET15b-HiPyrG following the manufacturer's instructions.
Expression and purification of recombinant PyrG. After cultivation of the transformed E. coli Rosetta-Gami B BL21(DE3) cells at 37 uC for 3 h in 250 ml LB broth containing 100 mg carbenicillin ml 21 , 1 mM IPTG was added and the cells were grown for a further 3-4 h at 30 uC. After centrifugation, the pellets containing the cells were resuspended in 10 ml bacterial protein extraction reagents (B-PER; Thermo Fisher Scientific), incubated at room temperature for 30 min and sonicated using a Biorupter (CosmoBio). After centrifugation of the lysates at 16 100 g for 15 min, the supernatants, containing the recombinant PyrG proteins tagged with 66His at their N terminus, were transferred to a column and incubated for 1 h with 2 ml Ni-NTA agarose resin slurry (Life Technologies Japan) that had been equilibrated with B-PER. The resin was then washed three times with 2 ml Wash Buffer 1 and twice with 3 ml Wash Buffer 2 (Thermo Fisher Scientific). Finally, the target protein -recombinant Strep. pneumoniae PyrG (SpPyrG) or H. influenzae PyrG (HiPyrG) -was eluted in 6 ml Elution Buffer (Thermo Fisher Scientific). Samples were analysed by SDS-PAGE and the purity of the target protein was determined by Coomassie Brilliant Blue (CBB) staining or immunoblotting with horseradish peroxidase-conjugated anti-His antibody Fig. 1 . Chemical structure of compound G1. The structure was drawn based on information from the supplier, and no chemical degradation was observed in this study (confirmed by liquid chromatography mass spectrometry). Fig. 2 . To determine PyrG activity in vitro, we examined the amount of residual substrate, ATP, after the reaction. The amount of ATP was measured using the luminescence-based ATP quantitative reagent Kinase-Glo (Promega). The PyrG reaction and the following luciferase reaction were carried out in a white 96-well half-area plate. SpPyrG (2 U per well) or HiPyrG (1.5 U per well) was mixed with 2 % (v/v) test inhibitor, which was serially diluted twofold in DMSO/methanol (70 : 30, v/v) , 70 mM HEPES, 0.5 mM Lglutamine, 0.5 mM EDTA, 10 mM MgCl 2 , 1 or 5 mM UTP (for the SpPyrG or HiPyrG assay, respectively) and 5 mM ATP in a total volume of 50 ml. After incubation for 2 h at 37 uC, 50 ml Kinase-Glo assay reagent was added to initiate the luciferase reaction, which was incubated for 10 min at room temperature. The level of luminescence was measured using an ARVO luminometer (Perkin Elmer) and expressed in relative luminescence units (RLU). The inhibitory activity (%) against PyrG was calculated according to the following formula:
Percentage inhibition51002(sample2minus-enzyme control)/(plusenzyme control2minus-enzyme control)6100
For the plus-enzyme positive control, a PyrG assay was performed in the absence of inhibitor. In the minus-enzyme negative control, sterile water was used instead of enzyme. The inhibition assay was performed using a twofold serial dilution ranging from 1 to 0.008 mg compound G1 ml
. The 50 % inhibitory concentration (IC 50 ) value was calculated using a linear regression standard curve calculated by two points that crossed the concentration of compound needed for 50 % inhibition. One unit of activity was defined as the amount of enzyme required to degrade 0.1 nmol ATP in 120 min at 37 uC under the conditions described above.
Susceptibility tests. MICs were determined using a standard microdilution broth method (CLSI, 2012) with slight modifications. Briefly, the inoculum size was~5610 5 c.f.u. ml 21 in a final assay volume of 50 ml. Twofold serial dilution plates inoculated with bacteria were incubated at 35 uC for 18-20 h, and the MIC was determined as the lowest concentration of the compound that completely inhibited viable growth of the organism in the microdilution wells.
Specificity analysis by NMR.
Conversion assay of glutamine to glutamate. The proton chemical shift change for the c position of glutamate caused by the PyrG reaction was measured using an AVANCE600 (Bruker Biospin) NMR device. Briefly, 10 % (v/v) DMSO-d 6 (Cambridge Isotope Laboratories) containing 500 mM of each test compound, PBS (pH 7.4), 10 mM MgCl 2 , 2 mM DTT, 0.5 mM ATP, 0.5 mM UTP, 0.5 mM glutamine and 1 mM SpPyrG were mixed in an NMR test tube (Shigemi) and incubated at room temperature for 2 h to convert glutamine to glutamate. After incubation, 10 mM EDTA was added to halt the reaction, and the proton spectrum was measured. The conversion rate (%) of glutamine to glutamate was calculated according to the formula: 1006B/A, where A is the proton signal intensity for the c position of glutamate in the absence of each test compound (100 % conversion control), and B is the proton signal intensity in the presence of test compound. An internal reference standard, 0.5 mM sodium 2,2-dimethyl-2-silapentane-5-sulfonate (Eurisotop), was used for all chemical shift measurements.
Binding assay by saturation transfer difference (STD) NMR spectroscopy. Binding assay monitoring of ATP or UTP binding to SpPyrG by STD NMR was performed as follows. DMSO-d 6 (10 %, v/v) containing 500 mM of each test compound, 50 mM Tris-d 11 (pH 7.5, Cambridge Isotope Laboratories), 150 mM NaCl, 5 mM MgCl 2 , 2 mM DTT, 0.1 mM ATP, 0.1 mM UTP and 10 mM SpPyrG were mixed, and the individual signal intensities in the STD spectrum were determined. Attenuation rates (%) of ATP or UTP were calculated according to the formula: 1006(C2D)/C, where C is the signal intensity in the STD spectrum of ATP or UTP in the absence of each test compound (0 % attenuation control) and D is the signal intensity in the STD spectrum in the presence of test compound. Each signal intensity in the STD spectrum was standardized according to the signal intensity obtained when not irradiated with the saturation pulse.
RESULTS AND DISCUSSION

Purification of SpPyrG and HiPyrG
In order to obtain recombinant PyrG proteins, SpPyrG or HiPyrG, each tagged with 66His at their N terminus, was expressed in E. coli and purified using Ni-affinity resin. When the purified SpPyrG or HiPyrG protein was examined by SDS-PAGE followed by CBB staining, a prominent band of 61.8 or 62.8 kDa, respectively, was detected, which was deduced to be the molecular mass of SpPyrG or HiPyrG (Fig. 3a, c) . These proteins were also detected by Western blot analysis with anti-His antibody (Fig. 3b, d ), suggesting that each of these proteins was the authentic target protein. A protein of~30 and~50 kDa was detected by CBB staining but not by Western blotting (Fig. 3a, b) , suggesting that these proteins were an endogenous protein in E. coli having an affinity for Ni-NTA agarose resin or were associated with SpPyrG. No ATPase activity was detected in the PyrG assay containing no UTP or glutamine, indicating that these proteins had almost no ATPase activity (data not shown).
Establishment of a PyrG (CTP synthase) assay
To evaluate the level of PyrG activity, the amount of residual substrate (ATP) in the reaction was measured. As shown in Fig. 4(a, b) , the RLU levels, which reflected the amount of ATP, decreased in a dose-dependent fashion with increasing amounts of SpPyrG or HiPyrG in the reaction, suggesting that the level of PyrG activity was inversely correlated with the amount of residual ATP.
Furthermore, the amount of UTP in the reaction, another substrate of PyrG, was also inversely correlated with the amount of residual ATP, whilst in the reference reaction (minus-enzyme control) there was no change in RLU levels influenzae PyrG activity. SpPyrG (a) and HiPyrG (b) were assayed at increasing UTP concentrations using Kinase-Glo reagent. SpPyrG (2 U per well) or HiPyrG (1.5 U per well) was used. In the negative-control reactions ("), sterilized water was added instead of PyrG.
( Fig. 5a, b) . In this assay, SpPyrG (2 U per well) or HiPyrG (1.5 U per well) was used.
To confirm that this assay system is applicable to evaluation of PyrG inhibitors, we validated the assay using acivicin, a glutamine analogue inhibitor of PyrG. Addition of acivicin increased the level of RLU in a dose-dependent manner, and acivicin inhibition of the ATPase activity of SpPyrG and HiPyrG was detected as IC 50 values of 1.2 and 0.51 mM, respectively ( Table 2) .
Evaluation of compound G1
The IC 50 values of compound G1 against SpPyrG and HiPyrG and the MICs against a number of different bacterial strains were examined (Table 2) . Compound G1 exhibited antimicrobial activity against Staph. aureus, H. influenzae DacrA and E. coli DtolC (strain with deletion of tolC, part of the AcrAB-TolC efflux pump system), and the IC 50 of compound G1 was less than that of acivicin. Acivicin is also known to be an inhibitor of other enzymes (Chittur et al., 2001; Miles et al., 2002) , and it is thought that the antimicrobial activity of acivicin does not depend on inhibition of PyrG activity, so acivicin susceptibility tests were not carried out. To further confirm inhibition of PyrG activity by compound G1, an assay of glutamine conversion to glutamate was performed by NMR. No glutamate (25 % as the conversion rate) was detected, suggesting that compound G1 inhibited PyrG activity in this assay. To elucidate the molecular mechanism underlying inhibition of PyrG by compound G1, a binding assay monitoring the binding of ATP and UTP to SpPyrG was performed by STD NMR spectroscopy. The signal attenuation rates of ATP and UTP were both 100 %, suggesting that compound G1 acts as an inhibitor of SpPyrG via loss of binding of ATP and/or UTP. It has been reported that ATP and UTP bind to E. coli PyrG in close proximity to each other (Endrizzi et al., 2005) , so compound G1 may be able to interact with the ATP and UTP binding sites bilaterally. We also confirmed by NMR the direct interaction of these compounds with SpPyrG (data not shown).
Taken together, we evaluated compound G1 as a specific inhibitor of PyrG. Although the antimicrobial activity of this compound was not strong enough for use clinically, we intend to characterize its structure further to facilitate the discovery of molecules superior to this prototype compound for use as antimicrobial agents.
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